Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Completed 20Recruiting 5Not yet recruiting 3Active not recruiting 3Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 5INDUSTRY 5NIH 1NETWORK 1FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Sarcoma 1

Conditions

Small Cell Lung Carcinoma 3Sarcoma, Ewing 1Sarcoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × PM 01183 × Clear all
NCT06203210 2026-06-02

IDeate-Lung02

Daiichi Sankyo

Phase 3 Recruiting
540 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06801834 2026-05-20

EVOKE-SCLC-04

Gilead Sciences

Phase 3 Recruiting
695 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07155174 2026-05-18

SEZanne

AbbVie

Phase 2 Recruiting
180 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05734066 2026-02-03

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Jazz Pharmaceuticals

Phase 1/2 Recruiting
60 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT06496048 2024-12-12

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Luye Pharma Group Ltd.

Phase 3 Recruiting
180 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡